Antwi SO, et al. - Using data from the Surveillance, Epidemiology, and End Results (SEER)-Medicare program (2009 to 2013), researchers studied associations of prediagnosis and postdiagnosis use of statins and metformin with the overall survival of patients with diabetes who later developed hepatocellular carcinoma (HCC). Study participants included 2,499 elderly diabetic patients with HCC. Findings suggested an association of prediagnosis use of metformin dose ≤ 1,500 mg/d with longer overall survival in elderly diabetic HCC patients. They did not, however, note any associations for prediagnosis metformin dose > 1,500 mg/d or postdiagnosis metformin use. In addition, no association for either prediagnosis or postdiagnosis statins use was evident.